Graduated in biochemistry, PhD from University of Hannover, Germany. Joined Boehringer Ingelheim in 1996, worked in various medical roles related to cardiovascular-renal metabolic indications, e.g. acute stroke treatment, stroke prevention, diabetes, chronic kidney disease. 2020-22 initiated and led a drug-agnostic global initiative for guideline implementation in type-2 diabetes. Since 2022 leading a global pipeline Medical Affairs team for a pipeline asset currently in phase III, evaluated for chronic kidney disease and heart failure.